Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bio Path Holdings Inc (NASDAQ:BPTH)

1.11
Delayed Data
As of Aug 28
 +0.04 / +3.74%
Today’s Change
0.99
Today|||52-Week Range
3.02
-58.27%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$99.6M

Company Description

Bio-Path Holdings, Inc. operates as a holding company, which through its subsidiary Bio-Path, Inc. develops novel cancer therapeutic products. It is licensed for developing three lead products and nucleric acid delivery technology, including tumor targeting technology. The company's lead product candidate, Liposomal Grb-2, is a liposomal antisense drug and is in a Phase I study for blood cancers. Its second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. Bio-Path Holdings was founded by Peter Nielsen, Gabriel Lopez-Berestein and Ana Maria Tari in May 2007 and is headquartered in Houston, TX.

Contact Information

Bio-Path Holdings, Inc.
2626 South Loop
Houston Texas 77054
P:(832) 971-6616
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Peter H. NielsenChairman, President, CEO, CFO, Treasurer & PAO
Ulrich W. MuellerChief Operating Officer
Ana Maria TariDirector-Preclinical Operations & Research
Tara SadeghiDirector-Clinical Operations